# Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

> **NCT02672358** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02672358
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-03
- **Primary completion:** 2019-09-02
- **Final completion:** 2020-12-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2018-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02672358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02672358, "Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02672358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*